Fed. Circ. Upholds Diazyme Win On Assays Patents
Ian Gilham, Axis-Shield's CEO, said that the company's attorneys were reviewing the decision but that unless they concluded that the court's reasoning was severely flawed, they would probably not appeal it.
“The most likely outcome is that we're going to accept it and move on,” he said.
The conflict centers on the companies’ enzymatic homocysteine...
To view the full article, register now.